Loncastuximab tesirine was more potent than other anti-CD19 ADCs (coltuximab ravtansine, huB4-DGN462), albeit the pattern of activity across cell lines was correlated. Loncastuximab tesirine activity was also largely correlated with cell line sensitivity to R-CHOP...Our data support the further development of loncastuximab tesirine as a single agent and in combination for patients affected by mature B-cell neoplasms. The results also highlight the importance of CD19 expression and the existence of lymphoma populations characterized by resistance to multiple therapies.

7 months ago

Preclinical • Journal • Combination therapy • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule)

CD19 positive • CD19 expression

Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • coltuximab ravtansine (SAR3419)

over4years

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models. (PubMed, Haematologica)

The response of B-cell lymphoma lines to huB4-DGN462 was not correlated with CD19 expression, the presence of BCL2 or MYC, TP53 inactivation or lymphoma histology. In conclusion, huB4-DGN462 is an attractive candidate for clinical investigation in patients with B-cell malignancies.

over 4 years ago

Journal

TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)

MYC expression

coltuximab ravtansine (SAR3419)